Positive LX2020 Phase 1/2 data disclosed by Lexeo (NASDAQ: LXEO) filing

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. reported positive interim Phase 1/2 clinical data for its gene therapy candidate LX2020 in PKP2-associated arrhythmogenic cardiomyopathy. On January 12, 2026, the company issued a press release describing these results and scheduled a conference call and webcast at 8:00 a.m. ET the same day to discuss the interim data. Lexeo also posted an updated LX2020-focused corporate presentation and a broader corporate presentation on its website, both of which, along with the press release, are attached as exhibits. The report includes standard cautionary language that future clinical progress, regulatory outcomes, and the company’s liquidity and capital resources are subject to significant risks and uncertainties.

Insights

Biotech equity analyst

Positive interim LX2020 data is a potentially meaningful but early milestone.

The company disclosed positive interim Phase 1/2 clinical data for LX2020, a gene therapy targeting PKP2-associated arrhythmogenic cardiomyopathy. Early-stage positive results can be important in rare disease gene therapy, as they may support continued development and future regulatory interactions, even though detailed efficacy and safety metrics are not provided here.

The same disclosure notes a same-day conference call and webcast and multiple related presentations, signaling that LX2020 is a strategic focus. However, the update is explicitly forward-looking in nature, and the company highlights risks around clinical progress, the link between preclinical and clinical outcomes, regulatory approvals, and capital resources. Subsequent SEC filings and clinical updates will determine how durable and clinically meaningful these interim results ultimately are.

0001907108false00019071082026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Lexeo Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41855	85-4012572
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
345 Park Avenue South, Floor 6
New York, New York				10010
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 212 547-9879

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		LXEO		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

The corporate presentation to be used in connection with the webcast described in Item 8.01 below is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On January 12, 2026, Lexeo Therapeutics, Inc. (the “Company”) issued a press release announcing positive interim Phase 1/2 clinical data of LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (“PKP2-ACM”). As part of the press release, the Company announced that it would be hosting a conference call and webcast at 8:00 a.m. ET on January 12, 2026 to discuss the interim Phase 1/2 clinical data of LX2020 for the treatment of PKP2-ACM. The press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Also on January 12, 2026, the Company posted on its website an updated corporate presentation (the “Corporate Presentation”). The Corporate Presentation will be used from time to time in meetings with investors and analysts. A copy of the Corporate Presentation is attached hereto as Exhibit 99.3 and is incorporated by reference herein.

Cautionary Note Regarding Forward-Looking Statements

This report contains certain forward-looking statements regarding the business of the Company that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s expected plans with respect to clinical trials of the Company’s gene therapy candidates and the timing for announcement of data from such trials. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, expectations regarding the initiation, progress, and expected results of the Company’s preclinical studies, clinical trials and research and development programs, the unpredictable relationship between preclinical study results and clinical study results, delays in submission of regulatory filings or failure to receive regulatory approval and liquidity and capital resources. Additional risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and subsequent future filings the Company may make with the Securities and Exchange Commission from time to time that are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements which are current only as of the date hereof. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press release issued by the Company on January 12, 2026, announcing Positive Interim Phase 1/2 Clinical Data of LX2020
99.2		Corporate Presentation (LX2020), dated January 12, 2026, furnished herewith
99.3		Corporate Presentation, dated January 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Lexeo Therapeutics, Inc.
Date:	January 12, 2026	By:	/s/ R. Nolan Townsend
			R. Nolan Townsend, Chief Executive Officer

FAQ

What did Lexeo Therapeutics (LXEO) announce in this 8-K?

Lexeo Therapeutics announced positive interim Phase 1/2 clinical data for its gene therapy candidate LX2020, which is being developed for PKP2-associated arrhythmogenic cardiomyopathy.

What is LX2020 and which condition is Lexeo targeting?

LX2020 is a gene therapy candidate being evaluated for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM), a heart muscle disorder linked to PKP2 gene variants.

Did Lexeo Therapeutics schedule a call to discuss the LX2020 data?

Yes. The company scheduled a conference call and webcast at 8:00 a.m. ET on January 12, 2026 to discuss the interim Phase 1/2 clinical data for LX2020.

What investor materials did Lexeo (LXEO) release with this update?

Lexeo furnished a press release, an LX2020-focused corporate presentation, and an updated corporate presentation as Exhibits 99.1, 99.2, and 99.3, respectively.

Are the LX2020 presentation materials considered filed with the SEC?

No. The corporate presentation attached as Exhibit 99.2 is described as furnished, not filed, meaning it is not subject to certain liability provisions of Section 18 of the Exchange Act unless specifically incorporated by reference elsewhere.

What risks and uncertainties does Lexeo highlight regarding LX2020 and its pipeline?

Lexeo notes risks related to the initiation, progress, and results of its preclinical studies and clinical trials, the unpredictable relationship between preclinical and clinical data, potential regulatory delays or failures, and its liquidity and capital resources.

Where can investors find more information on Lexeo Therapeutics risks?

The company directs readers to its Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and subsequent filings available at www.sec.gov.